Brokerages expect MorphoSys AG Unsponsored ADR (NYSE:MOR) to report ($0.38) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for MorphoSys’ earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.42). MorphoSys posted earnings per share of ($0.39) in the same quarter last year, which indicates a positive year-over-year growth rate of 2.6%. The company is expected to issue its next earnings report on Wednesday, March 11th.
On average, analysts expect that MorphoSys will report full year earnings of ($0.88) per share for the current fiscal year, with EPS estimates ranging from ($0.94) to ($0.82). For the next fiscal year, analysts forecast that the business will post earnings of ($0.64) per share, with EPS estimates ranging from ($1.31) to $0.03. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover MorphoSys.
Separately, Svb Leerink reissued an “outperform” rating on shares of MorphoSys in a research report on Tuesday, January 14th.
MOR stock traded down $0.72 during midday trading on Friday, reaching $30.76. 93,438 shares of the company’s stock traded hands, compared to its average volume of 116,426. MorphoSys has a fifty-two week low of $22.46 and a fifty-two week high of $37.96. The business has a 50-day moving average price of $33.54 and a two-hundred day moving average price of $30.59.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Featured Article: Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.